Oramed Pharmaceuticals to Present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CHODy), China 2011
Oramed to Present on Friday June 3, 2011
JERUSALEM, May 18, 2011 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that it was chosen to present at The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension in Shanghai, China. The presentation will be given by Roy Eldor M.D ., Director of Medical Affairs at Oramed, on Friday June 3, 2011 at 10:30 AM - 12:00 PM in Hall A at the exhibition center.
Event: The 1st Asia Pacific Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension
Date: Friday June 3, 2011
Time: 10:30 AM - 12:00 PM
For more information about the upcoming conference, please visit the following website: http://www.codhy.com/AP/2011/en-US/Default.aspx
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.
Company and Investor Relations Contact: Oramed Pharmaceuticals Tara Horn USA: +1-646-240-4193 Int'l: +972-54-334-4318 Email: email@example.com
SOURCE Oramed Pharmaceuticals Inc.
More by this Source
Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
May 17, 2013, 07:50 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.